共 39 条
- [21] Results of a phase III randomized, double-blind, placebo-controlled, multicenter trial (CORRECT) of regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients (pts) with metastatic colorectal cancer (mCRC) who have progressed after standard therapies.JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)Grothey, AxelSobrero, Alberto F.Siena, SalvatoreFalcone, AlfredoYchou, MarcLenz, Heinz-JosefYoshino, TakayukiCihon, FrankWagner, AndreaVan Cutsem, Eric
- [22] Results of a prospective randomized phase III T-SAR trial comparing trabectedin vs best supportive care (BSC) in patients with pretreated advanced soft tissue sarcoma (ASTS)ANNALS OF ONCOLOGY, 2016, 27Le Cesne, A.Blay, J-Y.Cupissol, D.Italiano, A.Delcambre, C.Penel, N.Isambert, N.Chevreau, C.Bompas, E.Bertucci, F.Chaigneau, L.Piperno-Neumann, S.Salas, S.Rios, M.Guillemet, C.Bay, J-O.Ray-Coquard, L.Mir, O.Haddag, L.Foulon, S.
- [23] MULTICENTRE PHASE III TRIAL COMPARING VINFLUNINE (V) PLUS BEST SUPPORTIVE CARE (BSC) VS BSC ALONE AS 2ND LINE THERAPY AFTER A PLATINUM-CONTAINING REGIMEN, IN ADVANCED TRANSITIONAL CELL CARCINOMA OF THE UROTHELIUM (TCCU)ANNALS OF ONCOLOGY, 2008, 19 : 202 - 202von der Maase, H.James, N.Winquist, E.Karyakin, O.Jagiello-Gruszfeld, A.Lorenz, J.van Herpen, C.Delgado, F.Salhi, Y.Bellmunt, J.
- [24] Preliminary safety, pharmacokinetics, and efficacy results from an open-label, multicenter, Phase I/II study of avapritinib in Chinese patients with unresectable or metastatic gastrointestinal stromal tumors (GIST).JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)Li, JianGong, JifangWang, XichengLi, JieLi, YanQi, ChangsongShen, LinRen, WenxiaoZhao, WanqiWang, YedongHu, JinRen, ChunliSong, WenjieYang, Jianxin
- [25] Phase IIb randomized trial of Pexa-Vec (pexastimogene devacirepvec; JX-594), a targeted oncolytic vaccinia virus, plus best supportive care (BSC) versus BSC alone in patients with advanced hepatocellular carcinoma who have failed sorafenib treatment (TRAVERSE)JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)Heo, JeongChao, YeeJonker, Derek J.Baron, Ari DavidHabersetzer, FrancoisBurke, JamesBreitbach, CarolinePatt, Richard H.Lencioni, RiccardoHomerin, MichelLimacher, Jean-MarcLusky, MonikaHickman, TheresaLongpre, LaraKirn, David H.
- [26] A multicentre, international, randomised, open-label phase 3 trial of avelumab plus best supportive care (BSC) vs BSC alone as maintenance therapy after first-line platinum-based chemotherapy in patients with advanced urothelial cancer (JAVELIN bladder 100)ANNALS OF ONCOLOGY, 2016, 27Powles, T.Grivas, P.Aragon-Ching, J. B.Faroun, Y.Kessler, E. R.Tomita, Y.Chakrabarti, D.Laliberte, R. J.Shnaidman, M.Petrylak, D.
- [27] Randomized, double-blind, multicenter, parallel-group, Phase II study of gefitinib (IRESSA) plus best supportive care (BSC) versus placebo plus BSC in chemotherapy-naive patients with advanced non-small-cell lung cancer and poor performance status (INSTEP)JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S340 - S340Goss, GlenwoodFerry, DavidLaurie, ScottWierzbicki, RafalThompson, JoyceBiesma, B.Duffield, EmmaGhiorghiu, SerbanZarenda, MarcArmour, Alison
- [28] GILT study: Oral vinorelbine (NVBo) and cisplatin (P) with concomitant radiotherapy (RT) followed by either consolidation (C) with NVBo plus P plus best supportive care (BSC) or BSC alone in stage (st) III non-small cell lung cancer (NSCLC): Final results of a phase (ph) III studyJOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)Huber, Rudolf M.Engel-Riedel, WalburgaKollmeier, JensAndreas, StefanStaar, SusanneKlautke, GuntherFietkau, RainerVaissiere, NathalieOsowski, SusanneFlentje, Michael
- [29] An open label, randomized phase III trial evaluating the treatment (tx) effects of panitumumab (pmab) plus best supportive care (BSC) versus BSC in chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC) and in WT RAS mCRC.JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)Kim, Tae WonElme, AnneliKusic, ZvonkoPark, Joon OhUdrea, Anghel AdrianKim, Sun YoungAhn, Joong BaeValencia, Ricardo VillalobosSrinivasan, KrishnanBilic, AnteManojlovic, NebojsaDong, JunGuan, XuesongLofton-Day, CatherineJung, A. ScottVrdoljak, Eduard
- [30] Final results of the CARACAS study: Randomized phase II trial of avelumab alone or with cetuximab for unresectable, locally advanced or metastatic squamous cell anal carcinoma progressed to at least one line of treatmentANNALS OF ONCOLOGY, 2020, 31 : S412 - S412Lonardi, S.Pietrantonio, F.Prete, A. A.Messina, M.Formica, V.Corsi, D. C.Cortesi, E.Frassineti, L. G.Zampino, M. G.Ronzoni, M.Scartozzi, M.Casagrande, M.Conca, V.Bergamo, F.Prisciandaro, M.Intini, R.Antista, M.Paola, D. B.Vettore, V.Zagonel, V.